Agios Pharmaceuticals (AGIO) – Research Analysts’ Weekly Ratings Changes

Agios Pharmaceuticals (NASDAQ: AGIO) recently received a number of ratings updates from brokerages and research firms:

  • 1/18/2018 – Agios Pharmaceuticals had its price target raised by analysts at Royal Bank of Canada to $91.00. They now have an “outperform” rating on the stock. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 1/16/2018 – Agios Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 1/16/2018 – Agios Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $84.00 price target on the stock. According to Zacks, “Agios received an FDA approval of Idhifa (enasidenib) in August for treatment of AML, which was a huge boost, given the immense commercial potential in the target market. We are also optimistic about its collaboration with Celgene as it provides Agios with regular funds. The company’s progress with the pipeline candidates, AG-120 and AG-881, has been quite impressive too. In December, the company submitted a new drug application to the FDA for  AG-120 for treatment of AML. Shares of the company have outperformed the industry in the last one year. However, Agios depends heavily on partner Celgene for revenues as Idhifa is only in the early stages of launch. Also, the decision to discontinue the development of AG-519 was disappointing. Stiff competition is another matter of concern for the company.”
  • 1/15/2018 – Agios Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Agios received an FDA approval of Idhifa (enasidenib) in August for treatment of AML, which was a huge boost, given the immense commercial potential in the target market. We are also optimistic about its collaboration with Celgene as it provides Agios with regular funds. The company’s progress with the pipeline candidates, AG-120 and AG-881, has been quite impressive too. In December, the company submitted a new drug application to the FDA for  AG-120 for treatment of AML. Shares of the company have outperformed the industry in the last one year. However, Agios depends heavily on partner Celgene for revenues as Idhifa is only in the early stages of launch. Also, the decision to discontinue the development of AG-519 was disappointing. Stiff competition is another matter of concern for the company.”
  • 1/9/2018 – Agios Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $68.00 price target on the stock. According to Zacks, “Agios received an FDA approval of Idhifa (enasidenib) in August for treatment of AML, which was a huge boost, given the immense commercial potential in the target market. We are also optimistic about its collaboration with Celgene as it provides Agios with regular funds. The company’s progress with the pipeline candidates, AG-120 and AG-881, has been quite impressive too. In December, the company submitted a new drug application to the FDA for  AG-120 for treatment of AML. Shares of the company have outperformed the industry in the last one year. However, Agios depends heavily on partner Celgene for revenues as Idhifa is only in the early stages of launch. Also, the decision to discontinue the development of AG-519 was disappointing. Stiff competition is another matter of concern for the company.”
  • 1/1/2018 – Agios Pharmaceuticals was given a new $83.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 12/31/2017 – Agios Pharmaceuticals was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 12/27/2017 – Agios Pharmaceuticals was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 12/26/2017 – Agios Pharmaceuticals was given a new $83.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 12/16/2017 – Agios Pharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 12/12/2017 – Agios Pharmaceuticals was given a new $90.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 12/11/2017 – Agios Pharmaceuticals had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $83.00 price target on the stock.
  • 12/5/2017 – Agios Pharmaceuticals had its “buy” rating reaffirmed by analysts at Cann. They wrote, “Agios announced on December 5, 2017 the appointment of Jacqualyn Fouse, Ph.D. to its board of directors. Dr. Fouse has served as executive chair of Dermavant since July 2017 and was previously chief operating officer of Celgene and member of Celgene’s board of directors.””

Shares of Agios Pharmaceuticals Inc (AGIO) opened at $69.89 on Monday. Agios Pharmaceuticals Inc has a 1 year low of $39.24 and a 1 year high of $76.02. The firm has a market capitalization of $3,410.00, a P/E ratio of -11.15 and a beta of 1.83.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.78) by $0.19. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The company had revenue of $11.35 million during the quarter, compared to analysts’ expectations of $10.85 million. During the same period last year, the firm earned ($1.63) EPS. The firm’s revenue for the quarter was up 26.4% on a year-over-year basis. research analysts predict that Agios Pharmaceuticals Inc will post -6.59 EPS for the current year.

In other news, CEO David P. Schenkein sold 53,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $73.16, for a total value of $3,877,480.00. Following the completion of the sale, the chief executive officer now directly owns 53,000 shares of the company’s stock, valued at approximately $3,877,480. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Scott Biller sold 2,146 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $62.69, for a total value of $134,532.74. The disclosure for this sale can be found here. Insiders have sold a total of 80,130 shares of company stock valued at $5,561,250 over the last ninety days. 5.43% of the stock is owned by insiders.

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Receive News & Ratings for Agios Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply